

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 21 1984

SUBJECT INDEX

- Acetylcholine depletion, 273
 AF64A
 ethylcholine aziridinium ion
 lesions, fimbria-fornix
 memory deficits
- ACTH, 513
 blood pressure
 dishabituation
 heart rate
 human studies
 neuropeptides
 vigilance
- Activity responses, 675
 castration
 nicotine
 sex differences
- Adrenal gland, 125
 catecholamines
 ethanol
 urinary excretion
- β -Adrenergic agonist, 313
 biting behavior
 chronic treatment
 clenbuterol
- Adrenergic receptors, 417
 prenatal stress
 tyrosine hydroxylation
- β -Adrenergic antagonists
 drinking, 883
 drug interaction, 883
 memory spread, 633
 propranolol, 633
 quantitative autoradiography, 633
 salt appetite, 883
- Beta-adrenergic blockade, 651
 food intake inhibition
 induced feeding
 propranolol
- Adrenoceptors, 267
 catalepsy
 chlorpromazine
 hypothalamus
 imipramine
 muricide
- AF64A, 273
 acetylcholine depletion
 ethylcholine aziridinium ion
 lesions, fimbria-fornix
 memory deficits
- Affective disorders, s49
 antidepressants
 rubidium
 schizophrenia
- Age differences, 671
 apomorphine
 social isolation
 stereotypy
- Aggregation, 969
 DSIP
 precursors
 protein binding
 social behavior
- Aggression, 495
 light cycle
 naloxone
 saline drinking
 social behavior
- Alcohol consumption, 387
 lithium chloride toxicosis
 odor aversion
- Alcohol dehydrogenase, s35
 aldehyde dehydrogenase
 cesium chloride
 ethanol
 hepatoma
 morbidity
- Aldehyde dehydrogenase
 alcohol dehydrogenase, s35
 cesium chloride, 235
 ethanol, s35
 hepatoma, s35
 lithium, s93
 morbidity, s35
 mortality, s93
 nitrogen dioxide, s93
- Alkali metals
 atria, s81
 cesium, s71
 chronotropic response, s81
 contractile force, s81
 heart rate, s81
 ionophores, s77
 ion transport, s77
 lithium, s71
 polyethylene glycols, s77
 potassium, s71
 rubidium, s71
 silacrown ethers, s77
 sodium, s71
- Alzheimer's disease, 169
 avoidance
 dementias
 memory
 retention
- Aminergic changes, 181
 apomorphine
 chronic lithium treatment
 social isolation
- Amphetamine, 97
 clozapine
 locomotor activity
 stereotypy
 thioridazine
 typical and atypical neuroleptics
- Amphetamine analogs, 895
 drug discrimination
 structure-activity studies
- d-Amphetamine
 body temperature, 575
 catecholamine, 321
 diazepam, 191
 fixed-interval schedules, 67
 greeting behavior, 191
 human studies, 67
 indomethacin, 219
 in vivo studies, 583
 ontogeny of rearing, 321
 operant behavior, 219, 279, 575, 583
 pigeons, 663
 prostaglandins, 219, 279, 575, 583
 rate-dependent drug effects, 67
 rectal temperature, 219
 rhesus monkeys, 191
 scopolamine, 321
 short-term memory, 663
 social behavior, 191
 time perception, 663
 verbal behavior, 67
- Amphibians, 213
 dextrorphan
 drug interaction
 levorphanol
 morphine
 naloxone
 opiates
- Analgesia
 anxiety, 749
 avoidance, 103
 cold pressor pain, 975
 human studies, 975
 inescapable shock, 749
 librium, 749
 MIF-1, 975
 morphine, 79
 morphine, prenatal exposure, 103
 naloxone, 681
 nociception, 133
 opiate antagonist, 937, 975
 pain, 79
 parachlorophenylalanine, 79
 PCPA, 681
 shuttle-escape deficit, 749
 stress, 103, 681
 tail-flick, 937
 threshold measurement, 133
 Tyr-MFI-1, 937

- up-and-down method, 133
- yohimbine, 681
- Anhedonia paradigm, 617
 - licking
 - pimozide
 - sucrose reward
- Animal model
 - cerebral blood flow, 891
 - cerebrovascular permeability, 891
 - depression, 487, 891
 - monoamines, 891
 - pyrazolodiazepine stress, 487
 - zometapine, 487
- Anorexia nervosa, s51
 - chemotherapy-induced neutropenia
 - lithium
 - metabolizing thyroid cancer
- Anti-conflict action, 521
 - benzodiazepine receptors
 - diazepam
 - GABA receptors
- Anticonvulsant
 - benzodiazepines, 137
 - electroconvulsive shock, 491
 - fominoben, 137
 - hypothermia, 491
 - THIP, 491
- Antidepressants
 - affective disorders, s49
 - chronic administration, 225
 - depression, 767
 - hypoactivity, 695
 - immobility, 767
 - intracerebral microinjection, 225
 - MIF-1, 767
 - muricide, 225
 - olfactory bulbectomy, 225
 - repeated treatment, antidepressants, 695
 - rubidium, s49
 - salbutamol, 695
 - schizophrenia, s49
 - Tyr-MIF-1, 767
- Antimuscarinic agents, 109
 - drug interaction
 - physostigmine
 - schedule-controlled behavior
- Antinociception
 - conditioned taste aversion, 591
 - enkephalinamide, 441
 - morphine, 591
 - naloxone, 591
 - opiate receptors, 591
 - vagal afferents, 441
- Antioxidants, s7
 - cancer
 - cesium
 - diet
 - essential fatty acids
 - vitamins
- Antipsychotic drugs, 645
 - brain stimulation
 - detection thresholds
- Anxiety
 - analgesia, 749
 - benzodiazepines, 839
 - clorazepate, 839
 - inescapable shock, 749
 - librium, 749
 - plasma corticosterone, 839
 - RO 15-1788, 839
 - shuttle-escape deficit, 749
 - stress, 839
- Anxiety model, 353
 - aversive brain stimulation
- ethyl alcohol
 - periaqueductal gray
- Anxiolytic agents
 - benzodiazepines, 965
 - chlordiazepoxide, 449
 - drinking, 965
 - NaCl intake, 449
 - punishment attenuation, 449
- Apparatus
 - cell harvester, 947
 - two-bar press, 19
- Apomorphine
 - age differences, 671
 - aminergic changes, 181
 - brain catecholamines, 733
 - chronic lithium treatment, 181
 - dopamine agonists, 237
 - dopamine autoreceptors, 301, 463
 - haloperidol, 463
 - inbred mice, 237
 - locomotor activity, 237
 - naloxone, 733
 - nigroraphe pathway, 301
 - open field, 85
 - pharmacogenetics, 237
 - serotonergic neurons, 301
 - sexual behavior, male rats, 463
 - social behavior, 85
 - social isolation, 181, 671
 - stereotypy, 85, 181, 237, 733
 - striatum, 301
- Atria, s81
 - alkali metals
 - chronotropic response
 - contractile force
 - heart rate
- Autoreceptors, 73
 - circling
 - locomotor asymmetries
 - substantia nigra
- Aversive brain stimulation, 353
 - anxiety model
 - ethyl alcohol
 - periaqueductal gray
- Avoidance
 - Alzheimer's disease, 169
 - analgesia, 103
 - body temperature, 561
 - central cholinergic receptors, 43
 - corticotropin-releasing factor, 707
 - dementias, 169
 - diisopropylfluorophosphate, 43
 - dopamine, 561
 - ethanol, 423
 - iodine-deficient diets, 561
 - locomotor activity, 561
 - memory, 43, 169
 - morphine, prenatal exposure, 103
 - naltrexone, 423
 - open field, 707
 - opiate antagonists, 423
 - plasma-corticosterone levels, 707
 - quinuclidinyl benzilate binding, 43
 - retention, 169
 - stress, 103
 - supersensitivity, 423
- Behavioral effects
 - cats, 913
 - drinking, 259
 - eating, 259
 - lesions, unilateral brain, 913
 - morphine, 913
 - opioid peptides, 259
 - reward, 259
 - stereotypy, 913
- Benzodiazepine antagonism, 381
 - CGS 8216
 - chlordiazepoxide
 - DRL responding
 - Ro 15-1788
- Benzodiazepine receptors, 521
 - anti-conflict action
 - diazepam
 - GABA receptors
- Benzodiazepines
 - anticonvulsant, 137
 - anxiety, 839
 - anxiolytic agent, 965
 - β -carboline, 667
 - chlordiazepoxide, 39, 667
 - clorazepate, 839
 - conflict situation, 773
 - constant light, 821
 - corticotropin (ACTH), 39
 - drinking, 965
 - drug preference, 865
 - FG 7142, 667
 - flurazepam, 865
 - fominoben, 137
 - hexobarbitone sleeping time, 39
 - human studies, 865
 - pineal, 821
 - plasma corticosterone, 839
 - Ro 15-1788, 839
 - self-stimulation, 667
 - self-stimulation, hypothalamus, 773
 - stimulation, dorsal central gray, 773
 - stress, 839
 - subjective effects, 865
 - superior cervical ganglionectomy, 821
- Bibliography, s113
 - cesium
- Bicuculline, 145
 - inferior colliculus
 - medial septum
 - site injections
 - substantia nigra
 - thyrotropin releasing hormone
- Biogenic amines, 289
 - 2-chloroadenosine
 - respiratory depression
- Biting behavior, 313
 - β -adrenergic agonist
 - chronic treatment
 - clenbuterol
- Blocking, 9
 - dorsal noradrenergic bundle
 - drug interaction
 - selective attention
- Blood, 761
 - delta-sleep inducing peptide
 - high performance liquid chromatography
 - sleep
- Blood-brain barrier, 943
 - carrier-mediated transport
 - N-tyrosinated peptides
- Blood ethanol levels, 255
 - ethanol self-selection
 - operant conditioning
- Blood pressure
 - ACTH, 513
 - carbon monoxide, s103
 - carboxyhemoglobin, s103
 - dishabituation, 513
 - heart rate, 103, 513
 - human studies, 513

- neuropeptides, 513
- respiration rate, s103
- vigilance, 513
- Blood pressure response, 393
 - passive avoidance
 - vasopressin
 - vasopressin fragments
 - vasopressor antagonists
- Body temperature
 - d-amphetamine, 575
 - avoidance, 561
 - bombesin, 197
 - dopamine, 561
 - iodine-deficient diets, 561
 - locomotor activity, 197, 561
 - neurotensin, 197
 - open field, 197
 - operant behavior, 575
 - prostaglandins, 575
- Body weight, 801
 - chronic drug injections
 - eating
 - hyperphagia
 - norepinephrine
 - paraventricular nucleus
- Bombesin, 197
 - body temperature
 - locomotor activity
 - neurotensin
 - open field
- Brain
 - amygdala, 225, 339
 - basal ganglia, 791
 - blood brain barrier, 177, 891
 - caudate nucleus, 29, 913, 929
 - central gray, 773
 - central nervous system, 145, 349, 913
 - cerebellum, s87, 151, 349, 481, 591
 - cerebral cortex, 349, 417
 - colliculi, 349
 - cortex, 151, 481
 - cuneate nucleus, 117
 - dorsal noradrenergic bundle, 357
 - dorsal raphe, 301
 - fimbria-fornix, 273
 - forebrain loci, 645
 - frontal cortex, 163
 - globus pallidus, 825
 - hippocampus, s87, 273, 301, 339, 481, 591
 - hypothalamus, 267, 339, 357, 481, 591, 645, 667, 773, 801
 - inferior colliculus, 145
 - lateral preoptic area, 267
 - locus coeruleus, 357, 891
 - medial forebrain bundle, 567
 - medulla-pons, 591
 - mesencephalic reticular formation, 853
 - mesencephalon, 339
 - midbrain, 481, 591
 - midbrain loci, 645
 - neocortex, 471
 - neostriatum, 929
 - nucleus accumbens, 501
 - paraventricular nucleus, 801
 - periaqueductal gray, 353, 853
 - pons-medulla, 349, 481
 - prefrontal cortex, 591
 - septum, 145
 - spinal cord, 349, 591
 - striatum, 53, s87, 273, 301, 339, 471, 481, 591, 853, 979
 - substantia nigra, 73, 89, 145, 301, 567
 - substantia nigra pars reticulata, 853
 - superior colliculus, 853
 - thalamus, 481
 - thalamus-hypothalamus, 349
 - vagus nerve, 441
 - ventral tegmental area, 567
- Brain catecholamines, 733
 - apomorphine
 - naloxone
 - stereotypy
- Brain monoamines
 - cholecystokinin octapeptide, 339
 - eating, 339
 - hypothalamic norepinephrine, 339
 - learned helplessness, 481
 - pituitary-gonadal axis, 481
- Brain plasticity, 349
 - differentially-housed mice
 - neurotransmitter amino acids
- Brain regions, s87
 - cesium
 - lithium
 - pharmacokinetics
 - rubidium
- Brain stimulation, 645
 - antipsychotic drugs
 - detection thresholds
- Brain-stimulation reward, 961
 - pentazocine
 - threshold determination
 - tripelennamine
- Caffeine
 - drug interaction, 375
 - eating, 33
 - exploration, 871
 - methylxanthines, 375
 - naloxone, 33
 - nicotine, 871
 - open field, 871
 - opioids, 33
 - L-phenylisopropyladenosine, 375
 - purines, 33
 - tolerance, 871
 - variable ratio, 375
 - wheelrunning, 871
- Cancer
 - antioxidants, s7
 - cesium, s7, s11, s25
 - colon carcinoma, s25
 - diet, s7, s11, s25
 - essential fatty acids, s7
 - human studies, s11
 - pH therapy, s25
 - vitamins, s7, s11
- Cancer therapy, s1
 - cesium
 - high pH
 - human studies
 - tumors
 - vitamins
- Cannabinoids, 61
 - drug discrimination
 - hypothermia
 - stereoisomers
- β -Carboline, 667
 - benzodiazepine
 - chlordiazepoxide
 - FG 7142
 - self-stimulation
- Carbon monoxide
 - blood pressure, s103
 - carboxyhemoglobin, s103
 - coronary flow, s99
 - heart rate, s99, s103
 - pulse pressure, s99
 - respiration rate, s103
- Carboxyhemoglobin, s103
 - blood pressure
 - carbon monoxide
 - heart rate
 - respiration rate
- Carrier-mediated transport, 943
 - blood-brain barrier
 - N-tyrosinated peptides
- Castration, 675
 - activity responses
 - nicotine
 - sex differences
- Catalepsy
 - adrenoceptors, 267
 - chlorpromazine, 267
 - GABA mechanisms, 825
 - globus pallidus, 825
 - hypothalamus, 267
 - imipramine, 267
 - locomotor activity, 825
 - muricide, 267
 - stereotypy, 825
- Catecholamines
 - adrenal gland, 125
 - d-amphetamine, 321
 - ethanol, 125
 - ontogeny of rearing, 321
 - scopolamine, 321
 - urinary excretion, 125
- (+)-Cathine, 1
 - (\pm)-cathinone
 - drug discrimination
 - drug interaction
 - structure-activity relationships
- (\pm)-Cathinone, 1
 - (+)-cathine
 - drug discrimination
 - drug interaction
 - structure-activity relationships
- Cats
 - behavioral effects, 913
 - cuneate nucleus, 117
 - dependence, 929
 - EEG, 923
 - electrical stimulation, 117
 - lesions, caudate nuclei, 929
 - lesions, unilateral brain, 913
 - morphine, 913, 923, 929
 - push-pull perfusion, 117
 - sleep-wakefulness, 923
 - stereotypy, 913
 - superficial radial nerve, 117
 - tolerance, 929
- Caudate nucleus, 29
 - 6-hydroxydopamine
 - methylamphetamine
 - neurotoxicity
- Cell harvester, 947
 - filtration
 - opiate receptors
- Central cholinergic receptors, 43
 - avoidance
 - diisopropylfluorophosphate
 - memory
 - quinuclidinyl benzilate binding
- Cerebellum, 151
 - convulsants
 - cortex
 - depressants
 - drug interaction
 - GABA receptor complex
- Cerebral blood flow, 891
 - animal model

- cerebrovascular permeability
 - depression
 - monoamines
- Cerebrovascular permeability, 891
 - animal model
 - cerebral blood flow
 - depression
 - monoamines
- Cesium
 - alkali metals, s71
 - antioxidants, s7
 - bibliography, s113
 - brain regions, s87
 - cancer, s7, s11, s25
 - cancer therapy, s1
 - cesium antipsychotic synergism, s17
 - cesium glucose interaction, s17
 - cesium vasopressor activity, s17
 - colon carcinoma, s25
 - diet, s7, s11, s15, s25
 - essential fatty acids, s7
 - hepatoma, s31
 - high pH, s1
 - human studies, s1, s11, s15
 - lithium, s71, s87
 - mortality, s27, s31
 - pharmacokinetics, s87
 - pH therapy, s25
 - positron radiodetection, s17
 - potassium, s27, s31, s71
 - potassium supplement, s15
 - rubidium, s71, s87
 - sarcoma, s27
 - sodium, s71
 - tumor, s1, s27
 - vitamins, s1, s7, s11, s15
- Cesium antipsychotic synergism, s17
 - cesium
 - cesium glucose interaction
 - cesium vasopressor activity
 - positron radiodetection
- Cesium chloride, s35
 - alcohol dehydrogenase
 - aldehyde dehydrogenase
 - ethanol
 - hepatoma
 - morbidity
- Cesium glucose interaction, s17
 - cesium
 - cesium antipsychotic synergism
 - cesium vasopressor activity
 - positron radiodetection
- Cesium vasopressor activity, s17
 - cesium
 - cesium antipsychotic synergism
 - cesium glucose interaction
 - positron radiodetection
- CGS 8216, 381
 - benzodiazepine antagonism
 - chlordiazepoxide
 - DRL responding
 - Ro 15-1788
- Chafing, 727
 - displacement activity
 - fish
 - naloxone
 - neuropeptides
 - thyrotropin-releasing hormone (TRH)
- Chemotherapy-induced neutropenia, s51
 - anorexia nervosa
 - lithium
 - metabolizing thyroid cancer
- Chloral hydrate, 599
 - flash evoked potentials
 - hyperthermia
- Chlordiazepoxide
 - anxiolytic agents, 449
 - benzodiazepine antagonism, 381
 - benzodiazepines, 39, 667
 - β -carboline, 667
 - CGS 8216, 381
 - conflict, 845
 - corticotropin (ACTH), 39
 - DRL responding, 381
 - FG 7142, 667
 - GABA, 845
 - hexobarbitone sleeping time, 39
 - NaCl intake, 449
 - Ro 15-1788, 381
 - punishment attenuation, 449
 - self-stimulation, 667
 - sodium valproate, 845
- 2-Chloroadrenosine, 289
 - biogenic amines
 - respiratory depression
- Chlorpromazine, 267
 - adrenoceptors
 - catalepsy
 - hypothalamus
 - imipramine
 - muricide
- Chlorprothixene, 721
 - delayed-matching-to-sample
 - haloperidol
 - neuroleptic drugs
 - pigeons
 - trifluoperazine
- Cholecystokinin, 755
 - lordosis
 - sexual behavior, female rats
- Cholecystokinin octapeptide, 339
 - brain monoamines
 - eating
 - hypothalamic norepinephrine
- Choline, 209
 - habituation
 - memory
 - nootropics
 - piracetam
- Chronic administration, 225
 - antidepressants
 - intracerebral microinjection
 - muricide
 - olfactory bulbectomy
- Chronic drug injections, 801
 - body weight
 - eating
 - hyperphagia
 - norepinephrine
 - paraventricular nucleus
- Chronic lithium treatment, 181
 - aminergic changes
 - apomorphine
 - social isolation
- Chronic treatment, 313
 - β -adrenergic agonist
 - biting behavior
 - clenbuterol
- Chronotropic response, s81
 - alkali rate
 - atria
 - contractile force
 - heart rate
- Cigarettes
 - human studies, 203, 903
 - magnitude estimation, 203
 - nicotine, 203
 - preference, 203
 - self-administration, 903
 - smoking, 903
 - taste, 203
 - temperature, 903
- Circadian cycle, 47
 - drinking
 - ethylketocyclazocine
 - water-deprivation
- Circling
 - autoreceptors, 73
 - GABA agonists, 853
 - locomotor asymmetries, 73
 - substantia nigra, 73
 - superior colliculus, 853
- Clenbuterol, 313
 - β -adrenergic agonist
 - biting behavior
 - chronic treatment
- Clorazepate, 839
 - anxiety
 - benzodiazepines
 - plasma corticosterone
 - Ro 15-1788
 - stress
- Clozapine, 97
 - amphetamine
 - locomotor activity
 - stereotypy
 - thioridazine
 - typical and atypical neuroleptics
- Cognition, 231
 - diazepam
 - learning
 - memory
 - psychomotor performance
 - route of administration
- Cold pressor pain, 975
 - analgesia
 - human studies
 - MIF-1
 - opiate antagonist
- Cold swim stress, 813
 - diazepam
 - flinch jump test
 - nociceptive thresholds
 - stress-induced analgesia
- Colon carcinoma, s25
 - cancer
 - cesium
 - diet
 - pH therapy
- Computerized bibliographic retrieval, s109
 - information systems
 - lithium
- Conditioned emotional response, 357
 - dorsal noradrenergic bundle
 - lesions, electrolytic
 - locus coeruleus
 - open field
- Conditioned place preference, 545
 - drug reinforcement
 - morphine extinction
- Conditioned taste aversion, 591
 - antinociception
 - morphine
 - naloxone
 - opiate receptors
- Conflict, 845
 - chlordiazepoxide
 - GABA
 - sodium valproate
- Conflict situation, 773
 - benzodiazepines
 - self-stimulation, hypothalamus
 - stimulation, dorsal central gray
- Constant light, 821
 - benzodiazepines

- pineal
 - superior cervical ganglionectomy
- Contractile force, s81
 - alkali metals
 - atria
 - chronotropic response
 - heart rate
- Contraversive circling, 567
 - electrical stimulation, medial forebrain bundle
 - locomotor activity
 - stimulus parameters
- Convulsants, 151
 - cerebellum
 - cortex
 - depressants
 - drug interaction
 - GABA receptor complex
- Coronary flow, s99
 - carbon monoxide
 - heart rate
 - pulse pressure
- Cortex, 151
 - cerebellum
 - convulsants
 - depressants
 - drug interaction
 - GABA receptor complex
- Corticotropin (ACTH), 39
 - benzodiazepines
 - chlordiazepoxide
 - hexobarbitone sleeping time
- Corticotropin-releasing factor, 707
 - avoidance
 - open field
 - plasma-corticosterone levels
- Cuneate nucleus, 117
 - cats
 - electrical stimulation
 - push-pull perfusion
 - superficial radial nerve
- Cysteamine, 833
 - locomotor activity
 - open field
 - somatostatin
- DA synthesis, 345
 - morphine withdrawal
 - Z-Pro-D-Leu
- Delayed-matching-to-sample, 721
 - chlorprothixene
 - haloperidol
 - neuroleptic drugs
 - pigeons
 - trifluoperazine
- Delta-sleep inducing peptide, 761
 - blood
 - high performance liquid chromatography
 - sleep
- Dementias, 169
 - Alzheimer's disease
 - avoidance
 - memory
 - retention
- Dependence, 929
 - cats
 - lesions, caudate nuclei
 - morphine
 - tolerance
- Depressant effects, 409
 - diazepam
 - drug discrimination
 - fixed ratio schedule
 - tolerance
- Depressants, 151
 - cerebellum
 - convulsants
 - cortex
 - drug interaction
 - GABA receptor complex
- Depression
 - animal model, 487, 891
 - antidepressant drugs, 767
 - cerebral blood flow, 891
 - cerebrovascular permeability, 891
 - immobility, 767
 - MIF-1, 767
 - Tyr-MIF-1, 767
 - monoamines, 891
 - pyrazolodiazepine stress, 487
 - zometapine, 487
- Desensitization, 177
 - drug interaction
 - locomotor activity
 - beta-receptor agonists
 - tachyphylaxis
- Detection thresholds, 645
 - antipsychotic drugs
 - brain stimulation
- Dexamphetamine, 53
 - excitatory afferents
 - multi-unit activity
 - striatum
- Dextrorphan, 213
 - amphibians
 - drug interaction
 - levorphanol
 - morphine
 - naloxone
 - opiates
- Diallel cross, 953
 - hypothermia
 - nicotine
 - pharmacogenetics
 - strain differences
- Diazepam
 - d-amphetamine, 191
 - anti-conflict action, 521
 - benzodiazepine receptors, 521
 - cognition, 231
 - cold swim stress, 813
 - depressant effects, 409
 - drug discrimination, 409
 - fixed ratio schedule, 409
 - flinch jump test, 813
 - GABA receptors, 521
 - greeting behavior, 191
 - learning, 231
 - memory, 231
 - nociceptive thresholds, 813
 - psychomotor performance, 231
 - rhesus monkeys, 191
 - route of administration, 231
 - social behavior, 191
 - stress-induced analgesia, 813
 - tolerance, 409
- Diet
 - antioxidants, s7
 - cancer, s7, s11, s25
 - cesium, s7, s11, s15, s25
 - colon carcinoma, s25
 - essential fatty acids, s7
 - human studies, s11, s15
 - pH therapy, s25
 - potassium supplement, s15
 - vitamins, s7, s11, s15
- Differentially-housed mice, 349
 - brain plasticity
 - neurotransmitter amino acids
- Diisopropyl fluorophosphate
 - avoidance, 43
 - central cholinergic receptors, 43
 - memory, 43, 467
 - muscarinic receptors, 467
 - quinuclidinyl benzilate binding, 43
 - [³H] quinuclidinyl benzilate binding, 43
 - retention, 467
- Discrimination, 19
 - drug discrimination
 - fixed-ratio schedule
 - two-bar press
- Dishabituation, 513
 - ACTH
 - blood pressure
 - heart rate
 - human studies
 - neuropeptides
 - vigilance
- Displacement activity, 727
 - chafing
 - fish
 - naloxone
 - neuropeptides
 - thyrotropin-releasing hormone (TRH)
- DOM
 - drug interaction, 281, 333
 - lisuride, 281
 - LSD, 281, 333
 - mescaline, 281
 - naloxone, 333
 - operant behavior, 281, 333
 - quipazine, 333
- Dopamine
 - avoidance, 561
 - body temperature, 561
 - estrogen, 791
 - iodine-deficient diets, 561
 - locomotor activity, 561, 791
 - postural deviation, 791, 979
 - rotation, 791, 979
 - striatum, 979
- Dopamine agonists, 237
 - apomorphine
 - inbred mice
 - locomotor activity
 - pharmacogenetics
 - stereotypy
- Dopamine autoreceptors
 - apomorphine, 301, 463
 - haloperidol, 463
 - nigrostriatal pathway, 301
 - serotonergic neurosis, 301
 - sexual behavior, male rats, 463
 - striatum, 301
- Dopamine receptors
 - drug discrimination, 185
 - lisuride, 185
 - muscarinic receptors, 297
 - nicotinic receptors, 297
 - tongue protruding, 297
 - yawning, 297
- Dorsal noradrenergic bundle
 - blocking, 9
 - conditioned emotional response, 357
 - drug interaction, 9
 - lesions, electrolytic, 357
 - locus coeruleus, 357
 - open field, 357
 - selective attention, 9
- Dorsomedial hypothalamic lesions, 245
 - eating

- growth retardation
 pancreatic enzymes
Drinking
 β -adrenergic antagonists, 883
 anxiolytic agent, 965
 behavioral effects, 259
 benzodiazepines, 965
 circadian cycle, 47
 drug interaction, 883, 965
 ethylketocyclazocine, 47
 GABA, 787
 homotaurine, 787
 opioid peptides, 259
 reward, 259
 salt appetite, 883
 voluntary intake of ethanol, 787
 water-deprivation, 47
DRL responding, 381
 benzodiazepine antagonism
 CGS 8216
 chlordiazepoxide
 Ro 15-1788
Drug
 AF64A, 273
 2-aminoindane, 895
 2-aminotetralin, 895
 amitriptyline, 225
 amphetamine, 97, 567, 641, 687, 715, 791, 895
 d-amphetamine, 67, 73, 185, 191, 219, 321, 431, 575, 583, 663, 727, 733
 apomorphine, 73, 85, 181, 185, 237, 297, 301, 459, 463, 501, 561, 567, 671
 arecoline hydrobromide, 169
 atropine, 109, 267
 baclofen, 89
 bicuculline, 145, 521, 825, 845, 853
 bicuculline methiodide, 89
 bromazepam, 773
 bromocriptine, 185
 butoxamine, 883
 [³⁵S]t-butylcyclophosphorothionate, 151
 caffeine, 33, 375, 871
 carbachol, 501
 carbon monoxide, s99, s103
 (+)-cathine, 1
 cathinone, 185, 895
 (\pm)-cathinone, 1
 R(+)-cathinone, 1
 S(-)-cathinone, 1
 cesium, s1, s7, s11, s15, s17, s25, s27, s31, s71, s81, s87, s113
 cesium chloride, s35
 CGS 8216, 381, 965
 chloral hydrate, 599
 chlordiazepoxide, 39, 381, 449, 667, 749, 845
 2-chloroadenosine, 289
 p-chlorophenylalanine, 859
 chlorpromazine, 225, 267, 431
 chlorprothixene, 721
 choline, 209
 clenbuterol, 177, 313
 clomipramine, 695
 clonidine, 181
 clorazepate, 839
 clozapine, 97, 501, 645
 cocaine, 185
 cysteamine, 833
 2-deoxy-D-glucose, 651
 desipramine, 225
 dexamphetamine, 53
 dextrorphan, 213
 diazepam, 191, 225, 231, 409, 431, 501, 521, 695, 773, 813, 865
 α -dihydroprototoxinin, 151
 diisopropylfluorophosphate, 43, 467
 DKJ-21, 109
 DOM, 281, 333
 L-DOPA, 459
 dopamine, 73, 185, 463, 583, 791, 979
 DSP-4, 163
 ethanol, s35, s87, 125, 255, 317, 329, 353, 387, 423, 521, 609, 787
 ethylketocyclazocine, 47
 [³H]-fentanyl, 705
 FG 7142, 667
 ³H-flunitrazepam, 137
 fluoxetine, 533
 alpha-flupenthixol, 73
 flurazepam, 865
 fominoben, 137
 francium, s71
 haloperidol, 185, 297, 463, 501, 567, 645, 695, 721
 hexamethonium, 527
 hexobarbitone, 39
 homotaurine, 787
 6-hydroxydopamine, 459
 5-hydroxytryptamine, 333
 imipramine, 267
 indomethacin, 219
 insulin, 651
 isopropylbicyclophosphate ester, 151
 isoproterenol, 9, 177, 883
 ketocyclazocine, 651
 levorphanol, 213
 lisuride, 185, 281, 501
 lithium, s49, s51, s57, s65, s71, s81, s87, s93, s109, 181
 lithium chloride, 387
 lorazepam, 865
 LSD, 281, 333, 501
 LY136596, 779
 LY150720, 779
 lysine vasopressin, 539
 marijuana, 641
 MDA, 453
 mecamylamine, 297, 527
 3-mercaptoproprionic acid, 137
 mescaline, 281
 methadone, 555, 743
 methamphetamine, 737
 methyldamphetamine, 29
 methyldatropine, 109
 methylphenidate, 641
 methylscopolamine, 297
 α -methyl-p-tyrosine, 345, 567, 859
 methylxanthine, 375
 metronidazole, 317
 mianserin, 695
 midazolam, 965
 MIF, 365
 morphiceptin, 705
 morphine, 79, 103, 133, 213, 259, 365, 369, 431, 545, 555, 591, 705, 779, 913, 923, 929, 937, 975
 Mr 2266, 507
 Mr-2266BS, 47
 muscimol, 89, 825, 845, 853
 naloxone, 5, 33, 47, 213, 259, 289, 333, 365, 441, 495, 507, 591, 651, 681, 699, 727, 733, 779, 937
 [³H]naloxone, 705
 naltrexone, 369, 423
 nialamide, 695
 nicotine, 203, 527, 675, 871, 953
 nitrogen dioxide, s93
 norepinephrine, 459, 801
 ORG 2766, 513
 oxotremorine, 133
 parachlorophenylalanine, 79
 paraxanthine, 375
 PCP, 159
 PCPA, 681
 penbutolol, 177
 pentamethylenetetrazole, 151
 pentazocine, 877, 961
 pentobarbital, 151, 431, 687
 pentylentetrazol, 137
 phencyclidine, 401, 453
 phenylisopropyladenosine, 289
 phenobarbital, 19, 687
 L-phenylisopropyladenosine, 375
 physostigmine, 109, 297, 551
 picrotoxin, 89, 501, 521, 825, 845, 853, 883
 picrotoxinin, 151
 pilocarpine, 297
 pimozide, 97, 345, 617
 piracetam, 209
 pirenerone, 185
 potassium, s1, s7, s27, s31, s71, s77, s81
 practolol, 177
 propranolol, 9, 177, 267, 633, 651
 puromycin, 633
 quipizine, 185, 333, 533
 reserpine, 567, 641
 Ro 5-4864, 821
 Ro 15-1788, 137, 381, 521, 839, 845, 965
 rubidium, s1, s7, s49, s71, s81, s87
 salbutamol, 177, 695, 883
 scopolamine, 297, 321, 471
 serotonin, 79, 401
 sodium, s7, s71, s77
 sodium chloride, 965
 sodium valproate, 845
 spisperone, 825
 sulpiride, 501
 Δ^9 -tetrahydrocannabinol (THC), 61, 641
 3'-hydroxy- Δ^9 -tetrahydrocannabinol, 61
 theobromine, 375
 theophylline, 289, 375
 thioridazine, 97
 toluene, 625
 trifluoperazine, 721
 tripelennamine, 877, 961
 yohimbine, 9, 681
 zinc, s25
 Z-Pro-D-Leu, 345
 zometapine, 487
Drug discrimination
 amphetamine analogs, 895
 cannabinoids, 61
 (+)-cathine, 1
 (\pm)-cathinone, 1
 depressant effects, 409
 diazepam, 409
 discrimination, 19
 dopamine receptors, 185
 drug interaction, 1, 877
 fixed-ratio schedule, 19, 409
 hypothermia, 61
 lisuride, 185
 mu-receptor, 877
 pentazocine, 877
 stereoisomers, 61
 structure-activity relationships, 1
 structure-activity studies, 895
 tolerance, 409

- tripelennamine, 877
- two-bar press, 19
- Drug interaction
 - β -adrenergic antagonists, 883
 - amphibians, 213
 - antimuscarinic agents, 109
 - anxiolytic agent, 965
 - benzodiazepines, 965
 - blocking, 9
 - caffeine, 375
 - (+)-cathine, 1
 - (\pm)-cathinone, 1
 - cerebellum, 151
 - convulsants, 151
 - cortex, 151
 - depressants, 151
 - desensitization, 177
 - dextrorphan, 213
 - DOM, 281, 333
 - dorsal noradrenergic bundle, 9
 - drinking, 883, 965
 - drug discrimination, 1, 877
 - exteroceptive stimuli, 687
 - GABA receptor complex, 151
 - generalization, 687
 - incremental repeated acquisition, 431
 - interoceptive stimuli, 687
 - learning, 431
 - lever press, 431
 - levorphanol, 213
 - lisuride, 281
 - locomotor activity, 177, 501
 - LSD, 281, 333
 - mescaline, 281
 - methylxanthines, 375
 - morphiceptine, 705
 - morphine, 213, 705
 - naloxone, 213, 333
 - nucleus accumbens, 501
 - operant behavior, 281, 333
 - opiates, 213
 - pentazocine, 877
 - L-phenylisopropyladenosine, 375
 - physostigmine, 109
 - picrotoxin, 501
 - pigeons, 687
 - quipazine, 333
 - beta-receptor agonists, 177
 - μ -receptor, 705, 877
 - salt appetite, 883
 - schedule-controlled behavior, 109
 - selective attention, 9
 - structure-activity relationships, 1
 - tachyphylaxis, 177
 - tripelennamine, 877
 - variable ratio, 375
- Drug preference, 865
 - benzodiazepines
 - flurazepam
 - human studies
 - subjective effects
- Drug reinforcement, 545
 - conditioned place preference
 - morphine extinction
- DSIP, 969
 - aggregation
 - precursors
 - protein binding
- DSP-4, 163
 - lateralization
 - spontaneous hyperactivity
- Earthworm wash, 655
 - chemoattractant
- isolation
 - snakes
 - vomeronasal system
- Eating
 - behavioral effects, 259
 - body weight, 801
 - brain monoamines, 339
 - caffeine, 33
 - cholecystokinin octapeptide, 339
 - chronic drug interactions, 801
 - dorsomedial hypothalamic lesions, 245
 - growth retardation, 245
 - hyperphagia, 801
 - hypothalamic norepinephrine, 339
 - naloxone, 33
 - norepinephrine, 801
 - opioid peptides, 259
 - opioids, 33
 - pancreatic enzymes, 245
 - paraventricular nucleus, 801
 - purines, 33
 - reward, 259
- EEG, 923
 - cats
 - morphine
 - sleep-wakefulness
- Electrical stimulation, 117
 - cats
 - cuneate nucleus
 - push-pull perfusion
 - superficial radial nerve
- Electrical stimulation, medial forebrain bundle, 567
 - contraversive circling
 - locomotor activity
 - stimulus parameters
- Electroconvulsive shock, 491
 - anticonvulsion
 - hypothermia
 - THIP
- Elements, s41
 - metals
 - poisoning
 - psychiatry
- Endorphins, 699
 - focal brain stimulation
 - opiate withdrawal
 - stimulation-produced analgesia
 - tolerance
- Enkephalinamide, 441
 - antinociception
 - vagal afferents
- Escape, 809
 - locomotor activity
 - passive avoidance
 - Tyr-MIF-I-analogs
- Essential fatty acids, s7
 - antioxidants
 - cancer
 - cesium
 - diet
 - vitamins
- Estrogen, 791
 - dopamine
 - locomotor activity
 - postural deviation
 - rotation
- Ethanol
 - adrenal gland, 125
 - alcohol dehydrogenase, s35
 - aldehyde dehydrogenase, s35
 - anxiety model, 353
 - aversive brain stimulation, 353
 - avoidance, 423
 - catecholamines, 125
 - cesium chloride, s35
 - hepatoma, s35
 - intravenous infusion, 609
 - metronidazole, 317
 - morbidity, s35
 - naltrexone, 423
 - neural tolerance, 317
 - neurohypophyseal peptides, 539
 - opiate antagonists, 423
 - periaqueductal gray, 353
 - reinforcement, 609
 - self-administration, 609
 - strain differences, 317
 - supersensitivity, 423
 - tolerance, 539
 - urinary excretion, 125
- Ethanol self-selection, 255
 - blood ethanol levels
 - operant conditioning
- Ethylcholine aziridinium ion, 273
 - acetylcholine depletion
 - AF64A
 - lesions, fimbria-fornix
 - memory deficits
- Ethylketocyclazocine, 47
 - circadian cycle
 - drinking
 - water-deprivation
- Excitatory afferents, 53
 - dexamphetamine
 - multi-unit activity
 - striatum
- Exploratory behavior
 - caffeine, 871
 - habituation, 859
 - indoleamines, 859
 - monoamines, 859
 - nicotine, 871
 - open field, 871
 - tolerance, 871
 - vasopressin, 859
 - wheelrunning, 871
- Exteroceptive stimuli, 687
 - drug interaction
 - generalization
 - interoceptive stimuli
 - pigeons
- Extinction, 533
 - fluoxetine
 - quipazine
 - serotonin
- FG 7142, 667
 - benzodiazepine
 - β -carboline
 - chlordiazepoxide
 - self-stimulation
- Filtration, 947
 - cell harvester
 - opiate receptors
- Fish, 727
 - chafing
 - displacement activity
 - naloxone
 - neuropeptides
 - thyrotropin-releasing hormone (TRH)
- Fixed-interval schedules, 67
 - d-amphetamine
 - human studies
 - rate-dependent drug effects
 - verbal behavior
- Fixed-ratio schedule
 - depressant effects, 409
 - diazepam, 409

- discrimination, 19
- drug discrimination, 19, 209
- methadone, 743
- multiple fixed-interval, 743
- tolerance, 409
- two-bar press, 19
- Flash evoked potentials, 599
 - chloral hydrate
 - hyperthermia
- Flinch jump test, 813
 - cold swim stress
 - diazepam
 - nociceptive thresholds
 - stress-induced analgesia
- Flurazepam, 865
 - benzodiazepines
 - drug preference
 - human studies
 - subjective effects
- Fluoxetine, 533
 - extinction
 - quipazine
 - serotonin
- Focal brain stimulation, 699
 - endorphins
 - opiate withdrawal
 - stimulation-produced analgesia
 - tolerance
- Fominoben, 137
 - anticonvulsant
 - benzodiazepines
- Food intake inhibition, 651
 - beta-adrenergic blockade
 - induced feeding
 - propranolol
- GABA
 - chlordiazepoxide, 845
 - conflict, 845
 - drinking, 787
 - homotaurine, 787
 - sodium valproate, 845
 - voluntary intake of ethanol, 787
- GABA agonists
 - circling, 853
 - muscimol, 89
 - self-injurious behavior, 89
 - self-mutilation, 89
 - superior colliculus, 853
- GABA mechanisms, 825
 - cataplexy
 - globus pallidus
 - locomotor activity
 - stereotypy
- GABA receptor complex, 151
 - cerebellum
 - convulsants
 - cortex
 - depressants
 - drug interaction
- GABA receptors, 521
 - anti-conflict action
 - benzodiazepine receptors
 - diazepam
- Gastrointestinal transit, 365
 - MIF
 - morphine
 - naloxone
 - narcotic antagonism
- Generalization, 687
 - drug interaction
 - exteroceptive stimuli
 - interoceptive stimuli
 - pigeons
- Genetic influences, 159
 - PCP-induced stimulation
 - strain differences
- Globus pallidus, 825
 - cataplexy
 - GABA mechanisms
 - locomotor activity
 - stereotypy
- Greeting behavior, 191
 - d-amphetamine
 - diazepam
 - rhesus monkeys
 - social behavior
- Growth retardation, 245
 - dorsomedial hypothalamic lesions
 - eating
 - pancreatic enzymes
- Habituation
 - choline, 209
 - exploratory behavior, 859
 - indoleamines, 859
 - locomotor activity, 551
 - memory, 209
 - monoamines, 859
 - motility, 551
 - nootropics, 209
 - piracetam, 209
 - physostigmine, 551
 - spectral analysis, 551
 - vasopressin, 859
- Haloperidol
 - apomorphine, 463
 - chlorprothixene, 721
 - delayed-matching-to-sample, 721
 - dopamine autoreceptors, 463
 - neuroleptic drugs, 721
 - pigeons, 721
 - sexual behavior, male rats, 463
 - trifluoperazine, 721
- Hamsters, 369
 - locomotor activity
 - opiates
 - sex differences, hamsters
- Heart rate
 - ACTH, 513
 - alkali metals, s81
 - atria, s81
 - blood pressure, s103, 513
 - carbon monoxide, s99, s103
 - carboxyhemoglobin, s103
 - chronotropic response, s81
 - contractile force, s81
 - coronary flow, s99
 - dishabituation, 513
 - human studies, 513
 - neuropeptides, 513
 - pulse pressure, s99
 - respiration rate, s103
 - vigilance, 513
- Hepatoma
 - alcohol dehydrogenase, s35
 - aldehyde dehydrogenase, s35
 - cesium, s31
 - cesium chloride, s35
 - ethanol, s35
 - morbidity, s35
 - mortality, s31
 - potassium, s31
- Hexobarbitone sleeping time, 39
 - benzodiazepines
 - chlordiazepoxide
 - corticotropin (ACTH)
- High performance liquid chromatography, 761
 - blood
 - delta-sleep inducing peptide
 - sleep
- High pH, s1
 - cancer therapy
 - cesium
 - human studies
 - tumors
 - vitamins
- Homotaurine, 787
 - drinking
 - GABA
 - voluntary intake of ethanol
- Hormone
 - estradiol benzoate, 791
 - estrogen, 755, 791
 - progesterone, 755
 - prolactin, 727
- 5-HT release, 401
 - 5-HT uptake
 - phencyclidine
 - serotonergic system
 - stereotypy
- 5-HT uptake, 401
 - 5-HT release
 - phencyclidine
 - serotonergic system
 - stereotypy
- Human studies
 - ACTH, 513
 - d-amphetamine, 67
 - analgesia, 975
 - benzodiazepines, 865
 - blood pressure, 513
 - cancer, s11
 - cancer therapy, s1
 - cesium, s1, s11, s15
 - cigarettes, 203, 903
 - cold pressor pain, 975
 - diet, s11, s15
 - dishabituation, 513
 - drug preference, 865
 - fixed-interval schedules, 67
 - flurazepam, 865
 - heart rate, 513
 - high pH, s1
 - lithium, s65
 - magnitude estimation, 203
 - MIF-1, 975
 - nephrotoxicity, s65
 - neuropeptides, 513
 - neurotoxicity, s65
 - nicotine, 203
 - opiate antagonist, 975
 - organic brain syndrome, s65
 - potassium supplement, s15
 - preference, 203
 - rate-dependent drug effects, 67
 - self-administration, 903
 - smoking, 903
 - subjective effects, 865
 - taste, 203
 - temperature, 903
 - tumors, s1
 - verbal behavior, 67
 - vigilance, 513
 - vitamins, s1, s11, s15
- Human studies, male, 329
 - learning
 - mental rehearsal
 - tolerance
- 6-Hydroxydopamine
 - caudate nucleus, 29

- Lesch-Nyhan syndrome, 459
- methylamphetamine, 29
- neonatal treatment, 459
- neuroleptics, 459
- neurotoxicity, 29
- self-mutilation, 459
- Hyperphagia, 801
 - body weight
 - chronic drug injections
 - eating
 - norepinephrine
 - paraventricular nucleus
- Hypoactivity, 695
 - antidepressants
 - repeated-treatment, antidepressants
 - salbutamol
- Hypothalamic norepinephrine, 339
 - brain monoamines
 - cholecystokinin octapeptide
 - eating
- Hypothalamus, 267
 - adrenoreceptors
 - catalepsy
 - chlorpromazine
 - imipramine
 - muricide
- Hypothermia
 - anticonvulsion, 491
 - cannabinoids, 61
 - chloral hydrate, 599
 - diallel cross, 951
 - drug discrimination, 61
 - electroconvulsive shock, 491
 - flash evoked potentials, 599
 - nicotine, 953
 - pharmacogenetics, 953
 - stereoisomers, 61
 - strain differences, 953
 - THIP, 491
- Imipramine, 267
 - adrenoceptors
 - catalepsy
 - chlorpromazine
 - hypothalamus
 - muricide
- Immobility, 767
 - antidepressant drugs
 - depression
 - MIF-1
 - Tyr-MIF-1
- Inbred mice, 237
 - apomorphine
 - dopamine agonists
 - locomotor activity
 - pharmacogenetics
 - stereotypy
- Incremental repeated acquisition, 431
 - drug interaction
 - learning
 - lever press
- Indoleamines, 859
 - exploratory behavior
 - habituation
 - monoamines
 - vasopressin
- Indomethacin, 219
 - d-amphetamine
 - operant behavior
 - prostaglandins
 - rectal temperature
- Induced feeding, 651
 - beta-adrenergic blockade
 - food intake inhibition
 - propranolol
- Inescapable shock, 749
 - analgesia
 - anxiety
 - librium
 - shuttle-escape deficit
- Interior colliculus, 145
 - bicuculline
 - medial septum
 - site injection
 - substantia nigra
 - thyrotropin releasing hormone
- Information systems, s109
 - computerized bibliographic retrieval
 - lithium
- Ingestive behavior, 507
 - opiate receptors
 - pigeons
 - stereoselectivity
- Interoceptive stimuli, 687
 - drug interaction
 - exteroceptive stimuli
 - generalization
 - pigeons
- Intracerebral microinjection, 225
 - antidepressants
 - chronic administration
 - muricide
 - olfactory bulbectomy
- Intravenous infusion, 609
 - ethanol
 - reinforcement
 - self-administration
- In vivo studies, 583
 - d-amphetamine
 - operant behavior
 - prostaglandins
- Iodine-deficient diets, 561
 - avoidance
 - body temperature
 - dopamine
 - locomotor activity
- Ionophores, s77
 - alkali metals
 - ion transport
 - polyethylene glycols
 - silacrown ethers
- Ion transport, s77
 - alkali metals
 - ionophores
 - polyethylene glycols
 - silacrown ethers
- Isolation, 655
 - chemoattractant
 - earthworm: wash
 - snakes
 - vomer nasal system
- Lateralization, 163
 - DSP-4
 - spontaneous hyperactivity
- Learned helplessness, 481
 - brain monoamines
 - pituitary-gonadal axis
- Learning
 - cognition, 231
 - drug interaction, 431
 - diazepam, 231
 - human studies, male, 329
 - incremental repeated acquisition, 431
 - lever press, 431
 - memory, 231
 - mental rehearsal, 329
 - psychomotor performance, 231
 - route of administration, 231
 - tolerance, 329
- Lesch-Nyhan syndrome, 459
 - 6-hydroxydopamine
 - neonatal treatment
 - neuroleptics
 - self-mutilation
- Lesions, caudate nuclei, 929
 - cats
 - dependence
 - morphine
 - tolerance
- Lesions, electrolytic, 357
 - conditioned emotional response
 - dorsal noradrenergic bundle
 - locus coeruleus
 - open field
- Lesions, fimbria-fornix, 273
 - acetylcholine depletion
 - AF64A
 - ethylcholine aziridinium ion
 - memory deficits
- Lesions, unilateral brain, 913
 - behavioral effects
 - cats
 - morphine
 - stereotypy
- Lever press, 431
 - drug interaction
 - incremental repeated acquisition
 - learning
- Levorphanol, 213
 - amphibians
 - dextrorphan
 - drug interaction
 - morphine
 - naloxone
 - opiates
- Librium, 749
 - analgesia
 - anxiety
 - inescapable shock
 - shuttle-escape deficit
- Licking, 617
 - anhedonia paradigm
 - pimozide
 - sucrose reward
- Lightcycle, 495
 - aggression
 - naloxone
 - saline drinking
 - social behavior
- Lisuride
 - DOM, 281
 - dopamine receptors, 185
 - drug discrimination, 185
 - drug interaction, 281
 - LSD, 281
 - mescaline, 281
 - operant behavior, 281
- Lithium
 - aldehyde dehydrogenase, s93
 - alkali metals, s71
 - anorexia nervosa, s51
 - brain regions, s87
 - cesium, s71, s87
 - chemotherapy-induced neutropenia, s51
 - computerized bibliographic retrieval, s109
 - human studies, s65
 - information systems, s109
 - metabolizing thyroid cancer, s51

- mortality, s93
- movement disorders, s57
- nephrotoxicity, s65
- neurotoxicity, s65
- nitrogen dioxide, s93
- organic brain syndrome, s65
- parkinsonism, s57
- pharmacokinetics, s87
- potassium, s71
- rubidium, s71, s87
- sodium, s71
- tardive dyskinesia, s57
- Lithium chloride toxicosis, 387
 - alcohol consumption
 - odor aversion
- Locomotor activity
 - amphetamine, 97
 - apomorphine, 237
 - avoidance, 561
 - body temperature, 197, 561
 - bombesin, 197
 - catalepsy, 825
 - clozapine, 97
 - contraversive circling, 567
 - cysteamine, 833
 - desensitisation, 177
 - dopamine, 561, 791
 - dopamine agonists, 237
 - drug interaction, 177, 501
 - electrical stimulation, medial forebrain
 - bundle, 567
 - escape, 809
 - estrogen, 791
 - GABA mechanisms, 825
 - globus pallidus, 825
 - habituation, 551
 - hamsters, 369
 - inbred mice, 237
 - iodine-deficient diets, 561
 - motility, 551
 - neurotensin, 197
 - nucleus accumbens, 501
 - open field, 197, 833
 - opiates, 369
 - passive avoidance, 809
 - pharmacogenetics, 237
 - physostigmine, 551
 - picrotoxin, 501
 - postural deviation, 791
 - psychostimulant, 641
 - beta-receptor agonists, 177
 - rotation, 791
 - sex differences, hamsters, 369
 - somatostatin, 833
 - spectral analysis, 551
 - stereotyped gnawing, 641
 - stereotypy, 97, 237, 825
 - stimulus parameters, 567
 - tachyphylaxis, 177
 - tetrahydrocannabinol, 641
 - thioridazine, 97
 - typical and atypical neuroleptics, 97
 - Tyr-MIF-1 analogs, 809
- Locomotor asymmetries, 73
 - autoreceptors
 - circling
 - substantia nigra
- Locus coeruleus, 357
 - conditioned emotional response
 - dorsal noradrenergic bundle
 - lesions, electrolytic
 - open field
- Lordosis, 755
 - cholecystokinin
 - sexual behavior, female rats
- LSD
 - DOM, 281, 333
 - drug interaction, 281, 333
 - lisuride, 281
 - mescaline, 281
 - naloxone, 333
 - operant behavior, 281, 333
 - quipazine, 333
- LY150720 (picenadol), 779
 - mixed-agonist-antagonist
 - opioids
 - schedule-controlled behavior
 - squirrel monkeys
- Magnitude estimation, 203
 - cigarettes
 - human studies
 - nicotine
 - preference
 - taste
- Maternal opiate dependence, 555
 - methadone
 - morphine
 - offspring analgesia
- MDA, 453
 - monkeys
 - phencyclidine
 - repeated acquisition
- Medial septum, 145
 - bicuculline
 - inferior colliculus
 - site injection
 - substantia nigra
 - thyrotropin releasing hormone
- Memory, 43
 - avoidance
 - central cholinergic receptors
 - diisopropylfluorophosphate
 - quinuclidinyl benzilate binding
- Memory
 - Alzheimer's disease, 169
 - avoidance, 169
 - choline, 209
 - cognition, 231
 - diazepam, 231
 - dementias, 169
 - diisopropyl fluorophosphate, 467
 - habituation, 209
 - learning, 231
 - muscarinic receptors, 467
 - nootropics, 209
 - piracetam, 209
 - psychomotor performance, 231
 - [³H]quinuclidinyl benzilate binding, 467
 - retention, 169, 467
 - route of administration, 231
- Memory deficits, 273
 - acetylcholine depletion
 - AF64A
 - ethylcholine aziridinium ion
 - lesions, fimbria-fornix
- Memory spread, 633
 - beta-adrenergic antagonist
 - propranolol
 - quantitative autoradiography
- Mental rehearsal, 329
 - human studies, male
 - learning
 - tolerance
- Mescaline, 281
 - DOM
 - drug interaction
 - lisuride
- LSD
 - operant behavior
- Metabolizing thyroid cancer, s51
 - anorexia nervosa
 - chemotherapy-induced neutropenia
 - lithium
- Metals, s41
 - elements
 - poisoning
 - psychiatry
- Methadone
 - fixed-ratio, 743
 - maternal opiate dependence, 555
 - morphine, 555
 - multiple fixed-interval, 743
 - offspring analgesia, 555
- Methamphetamine, 737
 - monoamines
 - rhesus monkeys
 - self-administration
 - tolerance
- Method
 - cold pressor test, 975
 - gel chromatography, 761, 969
 - high performance liquid
 - chromatography, 117, 761, 937
 - horseradish peroxidase, 301
 - lever press, 431
 - operant conditioning, 255
 - radial arm maze, 273
 - radioimmunoassay, 937
 - spectral analysis, 551
 - up-and-down method, 133
 - Vogel's conflict test procedure, 521
- Methylamphetamine, 29
 - caudate nucleus
 - 6-hydroxydopamine
 - neurotoxicity
- Methylxanthines, 375
 - caffeine
 - drug interaction
 - L-phenylisopropyladenosine
 - variable ratio
- Metronidazole, 317
 - ethanol
 - neural tolerance
 - strain differences
- MIF, 365
 - gastrointestinal transit
 - morphine
 - naloxone
 - narcotic antagonism
- MIF-1
 - analgesia, 975
 - antidepressant drugs, 767
 - cold pressor pain, 975
 - depression, 767
 - human studies, 975
 - immobility, 767
 - opiate antagonist, 975
 - Tyr-MIF-1
- Mixed agonist-antagonist, 779
 - LY150720 (picenadol)
 - opioids
 - schedule-controlled behavior
 - squirrel monkeys
- Monkeys, 453
 - MDA
 - phencyclidine
 - repeated acquisition
- Monoamines
 - animal model, 891
 - cerebral blood flow, 891
 - cerebrovascular permeability, 891
 - depression, 891

- exploratory behavior, 859
- habituation, 859
- indoleamines, 859
- methamphetamine, 737
- rhesus monkeys, 737
- self-administration, 737
- tolerance, 737
- vasopressin, 859
- Morbidity, s35
 - alcohol dehydrogenase
 - aldehyde dehydrogenase
 - cesium chloride
 - ethanol
 - hepatoma
- Morphiceptin, 705
 - drug interaction
 - morphine
 - μ receptor
- Morphine
 - amphibians, 213
 - analgesia, 79
 - antinociception, 591
 - behavioral effects, 913
 - cats, 913, 923, 929
 - conditioned taste aversion, 591
 - dependence, 929
 - dextrorphan, 213
 - drug interaction, 213, 705
 - EEG, 923
 - gastrointestinal transit, 365
 - lesions, caudate nuclei, 929
 - lesions, unilateral brain, 913
 - levorphanol, 213
 - maternal opiate dependence, 555
 - methadone, 555
 - MIF, 365
 - morphiceptin, 705
 - naloxone, 213, 365, 591
 - narcotic antagonism, 365
 - offspring analgesia, 555
 - opiate receptors, 591
 - opiates, 213
 - pain, 79
 - parachlorophenylalanine, 79
 - μ receptor, 705
 - sleep-wakefulness, 923
 - stereotypy, 913
 - tolerance, 929
- Morphine extinction, 545
 - conditioned place preference
 - drug reinforcement
- Morphine, prenatal exposure, 103
 - analgesia
 - avoidance
 - stress
- Morphine withdrawal, 345
 - DA synthesis
 - Z-Pro-D-Leu
- Mortality
 - aldehyde dehydrogenase, s93
 - cesium, s27, s31
 - hepatoma, s31
 - lithium, s93
 - nitrogen dioxide, s93
 - potassium, s27, s31
 - sarcoma, s27
 - tumor, s27
- Motility, 551
 - habituation
 - locomotor activity
 - physostigmine
 - spectral analysis
- Mouse killing, 5
 - naloxone
 - predation
- Movement disorders, 57
 - lithium
 - parkinsonism
 - tardive dyskinesia
- Multiple fixed-interval, 743
 - fixed-ratio
 - methadone
- Multi-unit activity, 53
 - dexamphetamine
 - excitatory afferents
 - striatum
- Muricide
 - adrenoceptors, 267
 - antidepressants, 225
 - catalepsy, 267
 - chlorpromazine, 267
 - chronic administration, 225
 - hypothalamus, 267
 - imipramine, 267
 - intracerebral microinjection, 225
 - olfactory bulbectomy, 225
- Muscarinic receptors
 - diisopropyl fluorophosphate, 467
 - dopamine receptors, 297
 - memory, 467
 - nicotinic receptors, 297
 - [³H]quinclidinyl benzilate binding, 467
 - retention, 467
 - tongue protruding, 297
 - yawning, 297
- Muscimol, 89
 - GABA agonists
 - self-injurious behavior
 - self-mutilation
- NaCl intake, 449
 - anxiolytic agents
 - chlordiazepoxide
 - punishment attenuation
- Naloxone
 - aggression, 495
 - amphibians, 213
 - analgesia, 681
 - antinociception, 591
 - apomorphine, 733
 - brain catecholamines, 733
 - caffeine, 33
 - chafing, 727
 - conditioned taste aversion, 591
 - dextrorphan, 213
 - displacement activity, 727
 - DOM, 333
 - drug interaction, 213, 333
 - eating, 33
 - fish, 727
 - gastrointestinal transit, 365
 - levorphanol, 213
 - lightcycle, 495
 - LSD, 333
 - MIF, 365
 - morphine, 213, 365, 591
 - mouse killing, 5
 - narcotic antagonism, 365
 - neuropeptides, 727
 - operant behavior, 333
 - opiate receptors, 591
 - opiates, 213
 - opioids, 33
 - PCPA, 681
 - predation, 5
 - purines, 33
 - quipazine, 333
 - saline drinking, 495
 - stereotypy, 733
 - social behavior, 495
 - stress, 681
 - thyrotropin-releasing hormone (TRH), 727
 - yohimbine, 681
- Naltrexone, 423
 - avoidance
 - ethanol
 - opiate antagonists
 - supersensitivity
- Narcotic antagonism, 365
 - gastrointestinal transit
 - MIF
 - morphine
 - naloxone
- Neonatal treatment, 459
 - 6-hydroxydopamine
 - Lesch-Nyhan syndrome
 - neuroleptics
 - self-mutilation
- Nephrotoxicity, s65
 - human studies
 - lithium
 - neurotoxicity
 - organic brain syndrome
- Neural tolerance, 317
 - ethanol
 - metronidazole
 - strain differences
- Neurohypophyseal peptides, 539
 - ethanol
 - tolerance
- Neuroleptics
 - chlorprothixene, 721
 - delayed-matching-to-sample, 721
 - haloperidol, 721
 - 6-hydroxydopamine, 459
 - Lesch-Nyhan syndrome, 459
 - neonatal treatment, 459
 - pigeons, 721
 - self-mutilation, 459
 - trifluoperazine, 721
- Neuropeptides
 - ACTH, 513
 - blood pressure, 513
 - chafing, 727
 - dishabituation, 513
 - displacement activity, 727
 - fish, 727
 - heart rate, 513
 - human studies, 513
 - naloxone, 727
 - thyrotropin-releasing hormone (TRH), 727
 - vigilance, 513
- Neurotensin, 197
 - body temperature
 - bombesin
 - locomotor activity
 - open field
- Neurotoxicity
 - caudate nucleus, 29
 - human studies, s65
 - 6-hydroxydopamine, 29
 - lithium, s65
 - methylamphetamine, 29
 - nephrotoxicity, s65
 - organic brain syndrome, s65
- Neurotransmitter amino acids, 349
 - brain plasticity
 - differentially housed mice
- Nicotine
 - activity responses, 675
 - caffeine, 871
 - castration, 675

- cigarettes, 203
- diallel cross, 953
- exploration, 871
- human studies, 203
- hypothermia, 953
- magnitude estimation, 203
- open field, 871
- pharmacogenetics, 953
- preference, 203
- saccharin, 527
- sex differences, 675
- strain differences, 953
- taste, 203
- taste aversion, 527
- tolerance, 871
- two-bottle choice, 527
- wheelrunning, 871
- Nicotinic receptors, 297
 - dopamine receptors
 - muscarinic receptors
 - tongue protruding
 - yawning
- Nigroraphe pathway, 301
 - apomorphine
 - dopamine autoreceptors
 - serotonergic neurons
 - striatum
- Nitrogen dioxide, s93
 - aldehyde dehydrogenase
 - lithium
 - mortality
- Nociception, 133
 - analgesia
 - threshold measurement
 - up-and-down method
- Nociceptive thresholds, 813
 - cold swim stress
 - diazepam
 - flinch jump test
 - stress-induced analgesia
- Nootropics, 209
 - choline
 - habituation
 - memory
 - piracetam
- Norepinephrine, 801
 - body weight
 - chronic drug injections
 - eating
 - hyperphagia
 - paraventricular nucleus
- Nucleus accumbens, 501
 - drug interaction
 - locomotor activity
 - picrotoxin
- Odor aversion, 387
 - alcohol consumption
 - lithium chloride toxicosis
- Offspring analgesia, 555
 - maternal opiate dependence
 - methadone
 - morphine
- Olfactory bulbectomy, 225
 - antidepressants
 - chronic administration
 - intracerebral microinjection
 - muricide
- Ontogeny of rearing, 321
 - d-amphetamine
 - catecholamines
 - scopolamine
- Open field
 - apomorphine, 85
 - avoidance, 707
 - body temperature, 197
 - bombesin, 197
 - caffeine, 871
 - conditioned emotional response, 357
 - corticotropin-releasing factor, 707
 - cysteamine, 833
 - dorsal noradrenergic bundle, 357
 - exploration, 871
 - lesions, electrolytic, 357
 - locomotor activity, 197, 833
 - locus coeruleus, 357
 - neurotensin, 197
 - nicotine, 871
 - organic solvent abuse, 625
 - plasma-corticosterone levels, 707
 - social behavior, 85
 - somatostatin, 833
 - stereotypy, 85
 - tolerance, 625, 871
 - toluene, 625
 - wheelrunning, 871
- Operant behavior
 - d-amphetamine, 219, 575, 583
 - blood ethanol levels, 255
 - body temperature, 575
 - DOM, 281, 333
 - drug interaction, 281, 333
 - ethanol self-selection, 255
 - indomethacin, 219
 - in vivo studies, 583
 - lisuride, 281
 - LSD, 281, 333
 - mescaline, 281
 - naloxone, 333
 - prostaglandins, 219, 575, 583
 - quipazine, 333
 - rectal temperature, 219
- Opiate antagonist
 - analgesia, 937, 975
 - avoidance, 423
 - cold pressor pain, 975
 - ethanol, 423
 - human studies, 975
 - MIF-1, 975
 - naltrexone, 423
 - supersensitivity, 423
 - tail-flick, 937
 - Tyr-MIF-1, 937
- Opiate receptors
 - antinociception, 591
 - cell harvesters, 947
 - conditioned taste aversion, 591
 - filtration, 947
 - ingestive behavior, 507
 - morphine, 591
 - naloxone, 591
 - pigeons, 507
 - stereoselectivity, 507
- Opiate withdrawal, 699
 - endorphins
 - focal brain stimulation
 - stimulation-produced analgesia
 - tolerance
- Opiates
 - amphibians, 213
 - dextrorphan, 213
 - drug interaction, 213
 - hamsters, 369
 - levorphanol, 213
 - locomotor activity, 369
 - morphine, 213
 - naloxone, 213
 - sex differences, hamsters, 369
- Opioids
 - caffeine, 33
 - eating, 33
 - LY150720 (picenadol), 779
 - mixed agonist-antagonist, 779
 - naloxone, 33
 - purines, 33
 - schedule-controlled behavior, 779
 - squirrel monkeys, 779
- Opioid peptides, 259
 - behavioral effects
 - drinking
 - eating
 - reward
- Organic brain syndrome, s65
 - human studies
 - lithium
 - nephrotoxicity
 - neurotoxicity
- Organic solvent abuse, 625
 - open field
 - tolerance
 - toluene
- Pain, 79
 - analgesia
 - morphine
 - parachlorophenylalanine
- Pancreatic enzymes, 245
 - dorsomedial hypothalamic lesions
 - eating
 - growth retardation
- Parachlorophenylalanine, 79
 - analgesia
 - morphine
 - pain
- Paraventricular nucleus, 801
 - body weight
 - chronic drug injections
 - eating
 - hyperphagia
 - norepinephrine
- Parkinsonism, s57
 - lithium
 - movement disorders
 - tardive dyskinesia
- Passive avoidance
 - blood pressure response, 393
 - escape, 809
 - locomotor activity, 809
 - Tyr-MIF-1 analogs, 809
 - vasopressin, 393
 - vasopressin fragments, 393
 - vasopressor antagonists, 393
- PCPA, 681
 - analgesia
 - naloxone
 - stress
 - yohimbine
- PCP-induced stimulation, 159
 - genetic influences
 - strain differences
- Pentazocine
 - brain stimulation reward, 961
 - drug discrimination, 877
 - drug interaction, 877
 - mu-receptor, 877
 - threshold determination, 961
 - tripleleannamine, 877, 961
- Peptide
 - ACTH, 513
 - arginine vasopressin, 539
 - bombesin, 197
 - cholecystokinin, 339, 755

- corticotropin (ACTH), 39
- corticotropin-releasing factor, 707
- delta-sleep inducing peptide, 761, 969
- endorphins, 259, 699
- met-enkephalin, 943
- GABA, 521
- [des-9-glycinamide]LVP, 539
- MIF-1, 767, 975
- neurotensin, 197
- somatostatin, 833
- THIP, 491
- thyrotropin releasing hormone, 145, 715, 727
- Try-MIF-1, 767, 937
- Tyr-MIF-1-analogs, 809
- N-Tyr-MIF-1, 943
- vasopressin, 393, 859
- Periaqueductal gray, 353
 - anxiety model
 - aversive brain stimulation
 - ethyl alcohol
- Perseverative responding, 715
 - signal detection theory
 - thyrotropin releasing hormone (TRH)
 - visual discrimination
- Pharmacogenetics
 - apomorphine, 237
 - diallel cross, 953
 - dopamine agonists, 237
 - hypothermia, 953
 - inbred mice, 237
 - locomotor activity, 237
 - nicotine, 953
 - stereotypy, 237
 - strain differences, 953
- Pharmacokinetics, s87
 - brain regions
 - cesium
 - lithium
 - rubidium
- Phencyclidine
 - 5-HT release, 401
 - 5-HT uptake, 401
 - MDA, 453
 - monkeys, 453
 - repeated acquisition, 453
 - serotonergic system, 401
 - stereotypy, 401
- L-Phenylisopropyladenosine, 375
 - caffeine
 - drug interaction
 - methylxanthines
 - variable ratio
- pH Therapy, s25
 - cancer
 - cesium
 - colon carcinoma
 - diet
- Physostigmine
 - antimuscarinic agents, 109
 - drug interaction, 109
 - habituation, 551
 - locomotor activity, 551
 - motility, 551
 - schedule-controlled behavior, 109
 - spectral analysis, 551
- Picrotoxin, 501
 - drug interaction
 - locomotor activity
 - nucleus accumbens
- Pigeons
 - d-amphetamine, 663
 - chlorprothixene, 721
 - delayed-matching-to-sample, 721
 - drug interaction, 687
 - exteroceptive, 687
 - generalization, 687
 - haloperidol, 721
 - ingestive behavior, 507
 - interoceptive stimuli, 687
 - neuroleptic drugs, 721
 - opiate receptors, 507
 - short-term memory, 663
 - stereoselectivity, 507
 - time perception, 663
 - trifluoperazine, 721
- Pimozide, 617
 - anhedonia paradigm
 - licking
 - sucrose reward
- Pineal, 821
 - benzodiazepines
 - constant light
 - superior cervical ganglionectomy
- Piracetam, 209
 - choline
 - habituation
 - memory
 - nootropics
- Pituitary-gonadal axis, 481
 - brain monoamines
 - learned helplessness
- Plasma corticosterone
 - anxiety, 839
 - avoidance, 707
 - benzodiazepines, 839
 - clorazepate, 839
 - corticotropin-releasing factor, 707
 - open field, 707
 - Ro 15-1788, 839
 - stress, 839
- Poisoning, s41
 - elements
 - metals
 - psychiatry
- Polyethylene glycols, s77
 - alkali metals
 - ionophores
 - ion transport
 - silacrown ethers
- Positron radiodetection, s17
 - cesium
 - cesium antipsychotic synergism
 - cesium glucose interaction
 - cesium vasopressor activity
- Postural deviation
 - dopamine, 791, 979
 - estrogen, 791
 - locomotor activity, 791
 - rearing, 471
 - rotation, 791, 979
 - scopolamine, 471
 - stereotypy, 471
 - striatum, 979
- Potassium
 - alkali metals, s71
 - cesium, s27, s31, s71
 - hepatoma, s31
 - lithium, s71
 - mortality, s27, s31
 - rubidium, s71
 - sarcoma, s27
 - sodium, s71
 - tumor, s27
- Potassium supplement, s15
 - cesium
 - diet
 - human studies
 - vitamins
- Precursors, 969
 - aggregation
 - DSIP
 - protein binding
- Predation, 5
 - mouse killing
 - naloxone
- Preference, 203
 - cigarettes
 - human studies
 - magnitude estimation
 - nicotine
 - taste
- Prenatal stress, 417
 - adrenergic receptors
 - tyrosine hydroxylation
- Propranolol
 - beta-adrenergic antagonist, 633
 - beta-adrenergic blockade, 651
 - food intake inhibition, 651
 - induced feeding, 651
 - memory spread, 633
 - quantitative autoradiography, 633
- Prostaglandins
 - d-amphetamine, 219, 575, 583
 - body temperature, 575
 - indomethacin, 219
 - in vivo studies, 583
 - operant behavior, 219, 575, 583
 - rectal temperature, 219
- Protein binding, 969
 - aggregation
 - DSIP
 - precursors
- Psychiatry, s41
 - elements
 - metals
 - poisoning
- Psychomotor performance, 231
 - cognition
 - diazepam
 - learning
 - memory
 - route of administration
- Psychostimulant, 641
 - locomotor activity
 - stereotyped gnawing
 - tetrahydrocannabinol
- Pulse pressure, s99
 - carbon monoxide
 - coronary flow
 - heart rate
- Punishment attenuation, 449
 - anxiolytic agents
 - chlordiazepoxide
 - NaCl intake
- Purines, 33
 - caffeine
 - eating
 - naloxone
 - opioids
- Push-pull perfusion, 117
 - cats
 - cuneate nucleus
 - electrical stimulation
 - superficial radial nerve
- Pyrazolodiazepine stress, 487
 - animal model
 - depression
 - zometapine
- Quantitative autoradiography, 633
 - beta-adrenergic antagonist
 - memory spread

- Quinclidinyl benzilate binding, 43
 - avoidance
 - central cholinergic receptors
 - diisopropylfluorophosphate
 - memory
- [³H]Quinclidinyl benzilate binding, 467
 - diisopropyl fluorophosphate
 - memory
 - muscarinic receptors
 - retention
- Quipazine
 - DOM, 333
 - drug interaction, 333
 - extinction, 533
 - fluoxetine, 533
 - LSD, 333
 - naloxone, 333
 - operant behavior, 333
 - serotonin, 533

- Rate-dependent drug effects, 67
 - d-amphetamine
 - fixed-interval schedules
 - human studies
 - verbal behavior
- Rearing, 471
 - postural deviation
 - scopolamine
 - stereotypy
- Beta-receptor agonists, 177
 - desensitization
 - drug interaction
 - locomotor activity
 - tachyphylaxis
- μ Receptor
 - drug discrimination, 877
 - drug interaction, 705, 877
 - morphiceptin, 705
 - morphine, 705
 - pentazocine, 877
 - tripeleannanine, 877
- Rectal temperature, 219
 - d-amphetamine
 - indomethacin
 - operant behavior
 - prostaglandins
- Reinforcement, 609
 - ethanol
 - intravenous infusion
 - self-administration
- Repeated acquisition, 453
 - MDA
 - monkeys
 - phencyclidine
- Repeated treatment, antidepressants, 695
 - antidepressants
 - hypoactivity
 - salbutamol
- Respiration rate, s103
 - blood pressure
 - carbon monoxide
 - carboxyhemoglobin
 - heart rate
- Respiratory depression, 289
 - biogenic amines
 - 2-chloroadenosine
- Retention
 - Alzheimer's disease, 169
 - avoidance, 169
 - dementias, 169
 - diisopropyl fluorophosphate, 467
 - memory, 169, 467
 - muscarinic receptors, 467
 - [³H]quinclidinyl benzilate binding, 467
- Reward, 259
 - behavioral effects
 - drinking
 - eating
 - opioid peptides
- Rhesus monkeys
 - d-amphetamine, 191
 - diazepam, 191
 - greeting behavior, 191
 - methamphetamine, 737
 - monoamines, 737
 - self-administration, 737
 - social behavior, 191
 - tolerance, 737
- Ro 15-1788
 - anxiety, 839
 - benzodiazepines, 839
 - benzodiazepine antagonism, 381
 - CGS 8216, 381
 - chlordiazepoxide, 381
 - clorazepate, 839
 - DRL responding, 381
 - plasma corticosterone, 839
 - stress, 839
- Rotation
 - dopamine, 791, 979
 - estrogen, 791
 - locomotor activity, 791
 - postural deviation, 791, 979
 - striatum, 979
- Route of administration, 231
 - cognition
 - diazepam
 - learning
 - memory
 - psychomotor performance
- Rubidium
 - affective disorders, s49
 - alkali metals, s71
 - antidepressants, s49
 - brain regions, s87
 - cesium, s71, s87
 - lithium, s71, s87
 - pharmacokinetics, s87
 - potassium, s71
 - schizophrenia, s49
 - sodium, s71
- Saccharin, 527
 - nicotine
 - taste aversion
 - two-bottle choice
- Salbutamol, 695
 - antidepressants
 - hypoactivity
 - repeated treatment, antidepressants
- Saline drinking, 495
 - aggression
 - lightcycle
 - naloxone
 - social behavior
- Salt appetite, 883
 - β-adrenergic antagonists
 - drinking
 - drug interaction
- Sarcoma, s27
 - cesium
 - mortality
 - potassium
 - tumor
- Schedule-controlled behavior
 - antimuscarinic agents, 109
 - drug interaction, 109
 - LY150720 (piconadol), 779
 - mixed agonist-antagonist, 779
 - opioids, 779
 - physostigmine, 109
 - squirrel monkeys, 779
- Schizophrenia, s49
 - affective disorders
 - antidepressants
 - rubidium
- Scopolamine
 - d-amphetamine, 321
 - catecholamine, 321
 - ontogeny of rearing, 321
 - postural deviation, 471
 - rearing, 471
 - stereotypy, 471
- Selective attention, 9
 - blocking
 - dorsal noradrenergic bundle
 - drug interaction
- Self-administration
 - cigarettes, 903
 - ethanol, 609
 - human studies, 903
 - intravenous infusion, 609
 - methamphetamine, 737
 - monoamines, 737
 - reinforcement, 609
 - rhesus monkeys, 737
 - smoking, 903
 - temperature, 903
 - tolerance, 737
- Self-injurious behavior, 89
 - GABA agonists
 - muscimol
 - self-mutilation
- Self-mutilation
 - GABA agonists, 89
 - 6-hydroxydopamine, 459
 - Lesch-Nyhan syndrome, 459
 - muscimol, 89
 - neonatal treatment, 459
 - neuroleptics, 459
 - self-injurious behavior, 89
- Self-stimulation, 667
 - benzodiazepine
 - β-carboline
 - chlordiazepoxide
 - FG 7142
- Self-stimulation, hypothalamus, 773
 - benzodiazepines
 - conflict situation
 - stimulation, dorsal central gray
- Serotonergic neurons, 301
 - apomorphine
 - dopamine autoreceptors
 - nigroraphe pathway
 - striatum
- Serotonergic system, 401
 - 5-HT release
 - 5-HT uptake
 - phencyclidine
 - stereotypy
- Serotonin, 533
 - extinction
 - fluoxetine
 - quipazine
- Sex differences, 675
 - activity responses
 - castration
 - nicotine
- Sex differences, hamsters, 369
 - hamsters
 - locomotor activity
 - opiates

- Sexual behavior, female rats, 755
 - cholecystokinin
 - lordosis
- Sexual behavior, male rats, 463
 - apomorphine
 - dopamine autoreceptors
 - haloperidol
- Short-term memory, 663
 - d-amphetamine
 - pigeons
 - time perception
- Shuttle-escape deficit, 749
 - analgesia
 - anxiety
 - inescapable shock
 - librium
- Signal detection theory, 715
 - perseverative responding
 - thyrotropin releasing hormone (TRH)
 - visual discrimination
- Silacrown ethers, s77
 - alkali metals
 - ionophores
 - ion transport
 - polyethylene glycols
- Site injection, 145
 - bicuculline
 - inferior colliculus
 - medial septum
 - substantia nigra
 - thyrotropin releasing hormone
- Sleep, 761
 - blood
 - delta-sleep inducing peptide
 - high performance liquid chromatography
- Sleep-wakefulness, 923
 - cats
 - EEG
 - morphine
- Smoking, 903
 - cigarettes
 - human studies
 - self-administration
 - temperature
- Snakes, 655
 - chemoattractant
 - earthworm wash
 - isolation
 - vomerolnasal system
- Social behavior
 - aggression, 495
 - d-amphetamine, 191
 - apomorphine, 85
 - diazepam, 191
 - greeting behavior, 191
 - lightcycle, 495
 - naloxone, 495
 - open field, 85
 - rhesus monkeys, 191
 - saline drinking, 495
 - stereotypy, 85
- Social isolation
 - age differences, 671
 - aminergic changes, 181
 - apomorphine, 181, 671
 - chronic lithium treatment, 181
 - stereotypy, 671
- Sodium, s71
 - alkali metals
 - cesium
 - lithium
 - potassium
 - rubidium
- Sodium valproate, 845
 - chlordiazepoxide
 - conflict
 - GABA
- Somatostatin, 833
 - cysteamine
 - locomotor activity
 - open field
- Spectral analysis, 551
 - habituation
 - locomotor activity
 - motility
 - physostigmine
- Spontaneous hyperactivity, 163
 - DSP-4
 - lateralization
- Squirrel monkeys, 779
 - LY150720 (piconadol)
 - mixed agonist-antagonist
 - opioids
 - schedule-controlled behavior
- Stereoisomers, 61
 - cannabinoids
 - drug discrimination
 - hypothermia
- Stereoselectivity, 507
 - ingestive behavior
 - opiate receptors
 - pigeons
- Stereotyped gnawing, 641
 - locomotor activity
 - psychostimulant
 - tetrahydrocannabinol
- Stereotypy
 - age differences, 671
 - amphetamine, 97
 - apomorphine, 85, 237, 671, 733
 - behavioral effects, 913
 - brain catecholamines, 733
 - cataplexy, 825
 - cats, 913
 - clozapine, 97
 - dopamine agonists, 237
 - GABA mechanisms, 825
 - globus pallidus, 825
 - 5-HT release, 401
 - 5-HT uptake, 401
 - inbred mice, 237
 - lesions, unilateral brain, 913
 - locomotor activity, 97, 237, 825
 - naloxone, 733
 - open field, 85
 - pharmacogenetics, 237
 - phencyclidine, 401
 - postural deviation, 471
 - rearing, 471
 - scopolamine, 471
 - serotonergic system, 401
 - social behavior, 85
 - social isolation, 671
 - stereotypy, 913
 - thioridazine, 97
 - typical and atypical neuroleptics, 97
- Stimulation, dorsal central gray, 773
 - benzodiazepines
 - conflict situation
 - self-stimulation, hypothalamus
- Stimulation-produced analgesia, 699
 - endorphins
 - focal brain stimulation
 - opiate withdrawal
 - tolerance
- Stimulus parameters, 567
 - contraversive circling
 - electrical stimulation, medial forebrain bundle
 - locomotor activity
- Strain differences
 - diallel cross, 953
 - ethanol, 317
 - genetic influences, 159
 - hypothermia, 953
 - metronidazole, 317
 - neural tolerance, 317
 - nicotine, 953
 - PCP-induced stimulation, 159
 - pharmacogenetics, 953
- Stress
 - analgesia, 103, 681
 - anxiety, 839
 - avoidance, 103
 - benzodiazepines, 839
 - clorazepate, 839
 - morphine, prenatal exposure, 103
 - naloxone, 681
 - PCPA, 681
 - plasma corticosterone, 839
 - Ro 15-1788, 839
 - yohimbine, 681
- Stress-induced analgesia, 813
 - cold swim stress
 - diazepam
 - flinch jump test
 - nociceptive thresholds
- Striatum
 - apomorphine, 301
 - dexamphetamine, 53
 - dopamine, 979
 - dopamine autoreceptors, 301
 - excitatory afferents, 53
 - multi-unit activity, 53
 - nigrostriatal pathway, 301
 - postural deviation, 979
 - rotation, 979
 - serotonergic neurons, 301
- Structure-activity relationships, 1
 - (+)-cathine
 - (±)-cathinone
 - drug discrimination
 - drug interaction
- Structure-activity studies, 895
 - amphetamine analogs
 - drug discrimination
- Subjective effects, 865
 - benzodiazepines
 - drug preference
 - flurazepam
 - human studies
- Substantia nigra
 - autoreceptors, 73
 - bicuculline, 145
 - circling, 73
 - inferior colliculus, 145
 - locomotor asymmetries, 73
 - medial septum, 145
 - site injection, 145
 - thyrotropin releasing hormone, 145
- Sucrose reward, 617
 - anhedonia paradigm
 - licking
 - pimozide
- Superior cervical ganglionectomy, 821
 - benzodiazepines
 - constant light
 - pineal
- Superficial radial nerve, 117
 - cats
 - cuneate nucleus

- electrical stimulation
- push-pull perfusion
- Superior colliculus, 853
 - circling
 - GABA agonists
- Supersensitivity, 423
 - avoidance
 - ethanol
 - naltrexone
 - opiate antagonists
- Tachyphylaxis, 177
 - desensitisation
 - drug interaction
 - locomotor activity
 - beta-receptor agonists
- Tail-flick, 937
 - analgesia
 - opiate antagonist
 - Tyr-MIF-1
- Tardive dyskinesia, s57
 - lithium
 - movement disorders
 - parkinsonism
- Taste, 203
 - cigarettes
 - human studies
 - magnitude estimation
 - nicotine
 - preference
- Taste aversion, 527
 - nicotine
 - saccharin
 - two-bottle choice
- Temperature, 903
 - cigarettes
 - human studies
 - self-administration
 - smoking
- Tetrahydrocannabinol, 641
 - locomotor activity
 - psychostimulant
 - stereotyped gnawing
- Thioridazine, 97
 - amphetamine
 - clozapine
 - locomotor activity
 - stereotypy
 - typical and atypical neuroleptics
- THIP, 491
 - anticonvulsion
 - electroconvulsive shock
 - hypothermia
- Threshold determination, 961
 - brain-stimulation reward
 - pentazocine
 - tripelennamine
- Threshold measurement, 133
 - analgesia
 - nociception
 - up-and-down method
- Thyrotropin-releasing hormone (TRH)
 - bicuculline, 145
 - chafing, 727
 - displacement activity, 727
 - fish, 727
 - inferior colliculus, 145
 - medial septum, 145
 - naloxone, 727
 - neuropeptides, 727
 - perseverative responding, 715
 - signal detection theory, 715
 - site injection, 145
 - substantia nigra, 145
 - visual discrimination, 715
- Time perception, 663
 - d-amphetamine
 - pigeons
 - short-term memory
- Tolerance
 - caffeine, 871
 - cats, 929
 - dependence, 929
 - depressant effects, 409
 - diazepam, 409
 - drug discrimination, 409
 - endorphins, 699
 - ethanol, 539
 - exploration, 871
 - fixed ratio schedule, 409
 - focal brain stimulation, 699
 - human studies, male, 329
 - learning, 329
 - lesions, caudate nuclei, 929
 - mental rehearsal, 329
 - methamphetamine, 737
 - monoamines, 737
 - morphine, 929
 - neurohypophyseal peptides, 539
 - nicotine, 871
 - open field, 625, 871
 - opiate withdrawal, 699
 - organic solvent abuse, 625
 - rhesus monkeys, 737
 - self-administration, 737
 - stimulation-produced analgesia, 699
 - toluene, 625
 - wheelrunning, 871
- Tongue protruding, 297
 - dopamine receptors
 - muscarinic receptors
 - nicotinic receptors
 - yawning
- Toluene, 625
 - open field
 - organic solvent abuse
 - tolerance
- Trifluoperazine, 721
 - chlorprothixene
 - delayed-matching-to-sample
 - haloperidol
 - neuroleptic drugs
 - pigeons
- Tripelennamine
 - brain-stimulation reward, 961
 - drug discrimination, 877
 - drug interaction, 877
 - pentazocine, 877, 961
 - mu-receptor, 877
 - threshold determination, 961
- Tumor
 - cancer therapy, s1
 - cesium, s1, s27
 - high pH, s1
 - human studies, s1
 - mortality, s27
 - potassium, s27
 - sarcoma, s27
 - vitamins, s1
- Two-bar press, 19
 - discrimination
 - drug discrimination
 - fixed-ratio schedule
- Two-bottle choice, 527
 - nicotine
 - saccharin
 - taste aversion
- Typical and atypical neuroleptics, 97
 - amphetamine
 - clozapine
 - locomotor activity
 - stereotypy
 - thioridazine
- Tyr-MIF-1
 - analgesia, 937
 - antidepressant drugs, 767
 - depression, 767
 - immobility, 767
 - MIF-1, 767
 - opiate antagonist, 937
 - tail-flick, 937
- Tyr-MIF-1 analogs, 809
 - escape
 - locomotor activity
 - passive avoidance
- N-tyrosinated peptides, 943
 - blood-brain barrier
 - carrier-mediated transport
- Tyrosine hydroxylation, 417
 - adrenergic receptors
 - prenatal stress
- Up-and-down method, 133
 - analgesia
 - nociception
 - threshold measurement
- Urinary excretion, 125
 - adrenal gland
 - catecholamines
 - ethanol
- Vagal afferents, 441
 - antinociception
 - enkephalinamide
- Variable ratio, 375
 - caffeine
 - drug interaction
 - methylxanthines
 - L-phenylisopropyladenosine
- Vasopressin
 - blood pressure, 393
 - exploratory behavior, 859
 - habituation, 859
 - indoleamines, 859
 - monoamines, 859
 - passive avoidance, 393
 - vasopressin fragments, 393
 - vasopressor antagonists, 393
- Vasopressin fragments, 393
 - blood pressure response
 - passive avoidance
 - vasopressin
 - vasopressor antagonists
- Vasopressor antagonists, 393
 - blood pressure response
 - passive avoidance
 - vasopressin
 - vasopressin fragments
- Verbal behavior, 67
 - d-amphetamine
 - fixed-interval schedules
 - human studies
 - rate-dependent drug effects
- Vigilance, 513
 - ACTH
 - blood pressure
 - dishabituation
 - heart rate
 - human studies
 - neuropeptides

- Visual discrimination, 715
 perseverative responding
 signal detection theory
 thyrotropin releasing hormone (TRH)
- Vitamins
 antioxidants, s7
 cancer, s7, s11
 cancer therapy, s1
 cesium, s1, s7, s11, s15
 diet, s7, s11, s15
 essential fatty acids, s7
 high pH, s1
 human studies, s1, s11, s15
 potassium supplement, s1, s15
 tumors, s1
- Voluntary intake of ethanol, 787
 drinking
 GABA
 homotaurine
- Vomeronasal system, 655
 chemoattractant
 earthworm wash
 isolation
 snakes
- Water-deprivation, 47
 circadian cycle
 drinking
 ethylketocyclazocine
- Wheelrunning, 871
 caffeine
 exploration
 nicotine
 open field
 tolerance
- Yawning, 297
 dopamine receptors
 muscarinic receptors
 nicotinic receptors
 tongue protruding
- Yohimbine, 681
 analgesia
 naloxone
 PCPA
 stress
- Z-Pro-D-Leu, 345
 DA synthesis
 morphine withdrawal
- Zometapine, 487
 animal model
 depression
 pyrazolodiazepine stress

AUTHOR INDEX

- Abel, D. A., 767
 Adams, M. A., 125
 Adler, C. M., 609
 Ahlenius, S., 463
 Akins, F. R., 687
 Albert, D. J., 5
 Altman, H., 467
 Amano, M., 401
 Ammassari-Teule, M., 103
 Andrews, J. S., 715
 Arkles, B., s77
 Asdourian, D., 853
- Baldino, F., Jr., 137
 Banks, W. A., 943
 Baudhuin, M. G., s109
 Bauer, R. H., 321
 Baumeister, A. A., 89, 459
 Baran, L., 695
 Bardo, M. T., 545, 591
 Barela, P., 369
 Beck, C. H. M., 85
 Belkien, L., 481
 Bell, M., 481
 Beninger, R. J., 533
 Bernardis, L. L., 245
 Bernet, F., 357
 Bhargava, H. N., 365
 Bigajska, K., 695
 Bloom, A. S., 733
 Bodnar, R. J., 79
 Boismare, F., 787
 Bollók, I., 833
 Bose, R., s17
 Bovier, Ph., 353
 Born, J., 513
 Breese, G. R., 145, 289, 459
 Brewer, A. K., s1, s25
 Brezenoff, H. E., 109
 Broekkamp, C. L., 353
 Brooks, S., 245
 Bruins, L., 197
 Bryant, H. U., 651
 Bryson, R., 675
 Burch, J. B., 953
 Burgess, J. W., 913, 923, 929
- Campbell, I. C., 671
 Campbell, J., 891
- Carney, J. M., 237, 375, 381
 Carter, R. B., 779
 Castellano, C., 103
 Castellanos, P. F., 969
 Caza, P. A., 9
 Cervo, L., 737
 Chambers, L. K., 471
 Cherkin, A., 169
 Chitkara, B., 871
 Chow, H. L., 85
 Chretien, P., 787
 Christ, H., 727
 Church, A. C., 633
 Cleary, J., 743
 Coderre, T. J., 681
 Collins, A. C., 953
 Collins, K. R., 617
 Commissaris, R. L., 333
 Cooper, S. J., 47
 Cordoba, F., 349
 Coy, D. H., 767, 809
 Crocker, A. D., 133, 561
 Crocker, J. M., 561
 Cronan, T., 675
 Croskell, H., 891
 Crump, S., 159
- Damjanov, I., 317
 Danti, S., 313
 Dantzer, R., 839
 Daoust, M., 787
 de Andres, I., 913, 923, 929
 De Jong, W., 393
 Deviche, P., 507
 Dewey, W. L., 61, 877
 De Wied, D., 393, 707
 de Wit, H., 865
 Drugan, R. C., 749
 Dum, J., 259
 Durcan, M. J., 671
 Durlach, J., 787
 Dyer, R. S., 599
 Dykstra, L. A., 779
- Ehrensing, R. H., 767, 937, 975
 Emerick, S. G., 459
 Engel, J. A., 521
- Fahn, S., 79
 Falk, J. L., 449, 965
 Fehm, H.-L., 513
 Fehn-Wolfsdorf, G., 513
 File, S. E., 667
 Fischman, A. J., 761, 809, 937, 969
 Flexner, J. B., 633
 Flexner, L. B., 633
 Flood, J. F., 169
 Fowler, S. C., 617
 Frances, H., 177, 313
 Frankenheim, J., 43
 Franklin, K. B. J., 73
 Freed, W. J., 159
 Fregly, M. J., 883
 Frye, G. D., 89, 145, 459
 Fulker, D. W., 953
 Furukawa, H., 401
 Furukawa, T., 297
- Gaffori, O., 393
 Galizio, M., 423
 Gardner, R., 43
 Geller, H. M., 137
 Geula, C., 853
 Geyer, M. A., 301
 Ghoneim, M. M., 231
 Giknis, M. L. A., 317
 Glennon, R. A., 1, 895
 Gold, R., 501
 Goldfinger, M. D., 117
 Goldschmidt, P. L., 177
 Gomita, Y., 773
 Gonzalez, L. P., 551
 Gorzalka, B. B., 755
 Gouvier, W. D., 687
 Graf, M. V., 761, 767, 969
 Gramling, S. E., 617
 Greist, J. H., s109
 Griffiths, R. R., 903
 Grupp, L. A., 255
- Halpern, M., 655
 Hara, C., 267
 Harris, C. M., 913, 929
 Harris, L. S., 61
 Hauck, A. E., 895
- Haug, T., 409
 Hayashi, T., 809
 Hayes, M. W., 19
 Hellhammer, D. H., 481
 Henck, J. W., 333
 Herberg, L. J., 667
 Herz, A., 259
 Hetzler, B. E., 599
 Hinman, D. J., 625
 Hinrichs, J. V., 231
 Hiramatsu, M., 401
 Hirst, M., 125
 Hódi, K., 345
 Hoffman, P. L., 539
 Höglund, A. U., 859
 Honor, J., 743
 Hovious, J. R., 555
 Hughes, C. W., 891
 Hymowitz, N., 109
- Ichimaru, Y., 773
 Inoue, T., 297
 Iwamoto, E. T., 527
- Jähkel, M., 181
 Jalfre, M., 209
 Janowsky, D. S., 641
 Jarrard, L. E., 273
 Jefferson, J. W., s109
 Jeste, D. V., 159
 Johanson, C. E., 737, 865
 Johnson, P., 237
 Joyce, J. N., 791, 979
- Kádár, T., 339
 Kaempf, G. F., 61
 Kallman, M. J., 61, 877
 Kameyama, T., 401
 Kant, G. J., 273
 Kastin, A. J., 761, 767, 809, 937, 943, 947, 969, 975
 Katz, R. J., 487
 Kelly, D. D., 813
 Kent, T. A., 891
 Király, C., 833
 Kirschenbaum, D. M., 655
 Klein, D. C., 821
 Klein, M. J., 191
 Koob, G. F., 641